Merck and Co Inc (MRK): MRK acquires—(private)

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	829
Posts	119615
Boards Moderated	14
Alias Born	09/05/2002

DewDiligence

Re: None

Tuesday, 05/21/2019 10:05:47 AM

Tuesday, May 21, 2019 10:05:47 AM

MRK acquires—(private)—Peloton Therapeutics for $1.05B up-front and $1.15B in contingent milestones:

https://finance.yahoo.com/news/merck-acquire-peloton-therapeutics-bolstering-104500062.html

Merck…and Peloton Therapeutics, Inc. today announced that the companies have entered into a definitive agreement under which Merck…will acquire privately held Peloton, a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2a (HIF-2a) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate is PT2977, a novel oral HIF-2a inhibitor in late-stage development for renal cell carcinoma (RCC).

Peloton had already filed papers with the SEC to IPO at a price range generating a market cap of ~$750M, so MRK is paying a material premium, even without the contingent milestones.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”